VIDA Diagnostics, a Coralville, Iowa-based medical imaging company, has announced a new distribution deal with TeraRecon.
As a result of the agreement, VIDA’s LungPrint solution will be available to use on TeraRecon’s EnvoyAI platform. LungPrint is an imaging suite focused on using AI to provide pulmonary care to patients.
“VIDA is a valuable addition to our partner eco-system, offering physicians premium lung analysis and characterization AI with an integrated user experience that can only be achieved when interoperability is prioritized,” Jeff Sorenson, CEO and president of TeraRecon, said in a prepared statement. “Our customers have come to expect clinical workflow excellence for optimal patient care, and VIDA's LungPrint solution brings another best-in-class application to our wide portfolio of AI algorithms available directly within our customers' interpretation workflow.”
“VIDA and TeraRecon have a shared goal of equipping care teams with cutting-edge, clinically validated AI solutions,” Susan A. Wood, PhD, CEO of VIDA, said in the same statement. “We are excited to be partnering with TeraRecon; their AI platform elegantly integrates novel AI solutions like ours into the radiology workflow, which is a critical requirement in driving broad AI adoption in healthcare.”
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.